1 citations
,
January 2022 in “European Journal of Pharmacology” In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.
June 2026 in “Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)” This study observed that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from doxorubicin-induced damage while enhancing doxorubicin's effectiveness in prostate cancer cells, outperforming dexrazoxane's effects without compromising the anti-cancer efficacy.
This study concluded that pretreatment with finasteride or bicalutamide did not significantly affect the heat sensitivity of prostate cancer cells, although some cell lines showed increased viability at higher temperatures.
August 2025 in “Therapeutics” In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.